ACADIA Pharmaceuticals Inc. ACAD
NASDAQ · United States · Health Technology
$20.15-0.07 (-0.35%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled "Methods and Compositions for Treatment of Rett Syndrome." The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrati
AMTX, ACAD, and REZI are drawing attention from options bears
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.